Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases

Journal of Pharmacology and Experimental Therapeutics

Volumn 364, Issue 3, 2018, Pages 494-503

  Hilberg, Frank ^a   Tontsch Grunt, Ulrike ^a   Baum, Anke ^a   Le, Anh T ^b   Doebele, Robert C ^b   Lieb, Simone ^a   Gianni, Davide ^a,c   Voss, Tilman ^a   Garin Chesa, Pilar ^a   Haslinger, Christian ^a   Kraut, Norbert ^a  

^a BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CEDIRANIB; DISCOIDIN DOMAIN RECEPTOR 1; DISCOIDIN DOMAIN RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMATINIB; NINTEDANIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TROPOMYOSIN; TROPOMYOSIN RECEPTOR KINASE A; TROPOMYOSIN RECEPTOR KINASE C; UNCLASSIFIED DRUG; VANDETANIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IC50; INFANT; KATO III CELL LINE; MFM-223 CELL LINE; MOLM-13 CELL LINE; MOUSE; MUTATION; MV4-11 CELL LINE; NCI-H1703 CELL LINE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENETICS; LUNG TUMOR; ONCOGENE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; MUTATION; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85051295533     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.244129     Document Type: Article

References (55)

1. Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, Heisler LE, Beck TA, Simpson JT, Tonon L, et al. (2015) A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun 6: 10001.
2. Bengtsson H, Irizarry R, Carvalho B, and Speed TP (2008) Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 24:759-767.
3. Bengtsson H, Wirapati P, and Speed TP (2009) A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25:2149-2156.
4. Berge EM and Doebele RC (2014) Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 41:110-125.
5. Blackhall F and Cappuzzo F (2016) Crizotinib: from discovery to accelerated development to front-line treatment. Ann Oncol 27 (Suppl 3):iii35-iii41.
6. Boere IA, Hamberg P, and Sleijfer S (2010) It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci 101:7-15.
7. Bronte G, Passiglia F, Galvano A, Barraco N, Listì A, Castiglia M, Rizzo S, Fiorentino E, Bazan V, and Russo A (2016) Nintedanib in NSCLC: evidence to date and place in therapy. Ther Adv Med Oncol 8:188-197.
8. Camps J, Morales C, Prat E, Ribas M, Capellà G, Egozcue J, Peinado MA, and Miró R (2004) Genetic evolution in colon cancer KM12 cells and metastatic derivates. Int J Cancer 110:869-874.
9. Cancer Genome Atlas Research Network (2014a) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209.
10. Cancer Genome Atlas Research Network (2014b) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322.
11. Capdeville R, Buchdunger E, Zimmermann J, and Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
12. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, et al. (2014) Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20: 6551-6558.
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
14. Cesca M, Morosi L, Berndt A, Fuso Nerini I, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S, et al. (2016) Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response. Mol Cancer Ther 15:125-135.
15. Chu CT, Sada YH, and Kim ES (2012) Vandetanib for the treatment of lung cancer. Expert Opin Investig Drugs 21:1211-1221.
16. Culy C (2005) Bevacizumab: antiangiogenic cancer therapy. Drugs Today (Barc) 41: 23-36.
17. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, and Tabernero J (2014) Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 25:552-563.
18. Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, et al. (2015) Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 21: 3307-3317.
19. Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, et al. (2015) An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 5:1049-1057.
20. Döhner H, Weisdorf DJ, and Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136-1152.
21. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, and Bhalla KN (2014) BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther 13:2315-2327.
22. Gasparini G, Longo R, Fanelli M, and Teicher BA (2005a) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23:1295-1311.
23. Gasparini G, Longo R, Toi M, and Ferrara N (2005b) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2:562-577.
24. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, Swamy S, Santarius T, Chen L, Widaa S, et al. (2010) PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 11: 164-175.
25. Greuber EK, Smith-Pearson P, Wang J, and Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13: 559-571.
26. Guerrot D, Kerroch M, Placier S, Vandermeersch S, Trivin C, Mael-Ainin M, Chatziantoniou C, and Dussaule JC (2011) Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 179:83-91.
27. Heldin CH (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 11:97.
28. Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, and Fox SB (2016) The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol 7: 621.
29. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, et al. (2016) FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Sci 107:1667-1676.
30. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774-4782.
31. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19 (4, Suppl 3):7-16.
32. Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605-622.
33. Jayson GC, Kerbel R, Ellis LM, and Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388:518-529.
34. Kang S, Bader AG, and Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802-807.
35. Katoh M (2016) FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 38:3-15.
36. Kerbel RS (2015) A decade of experience in developing preclinical models of advanced-or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J 21: 274-283.
37. Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, et al. (2006) Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther 5:3105-3112.
38. Lee CH and Motzer RJ (2015) Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. Urol Oncol 33:275-279.
39. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, and Durbin R; 1000 Genome Project Data Processing Subgroup (2009) The sequence alignment/Map format and SAMtools. Bioinformatics 25:2078-2079.
40. Li Y, Gao ZH, and Qu XJ (2015) The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol 116:216-221.
41. Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, Malatesta S, Chella A, Barassi F, Mucilli F, et al. (2008) Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 29:609-616.
42. Moschetta M, Cesca M, Pretto F, and Giavazzi R (2010) Angiogenesis inhibitors: implications for combination with conventional therapies. Curr Pharm Des 16: 3921-3931.
43. Olaso E, Lin HC, Wang LH, and Friedman SL (2011) Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling. Fibrogenesis Tissue Repair 4:5.
44. Quentmeier H, Reinhardt J, Zaborski M, and Drexler HG (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17:120-124.
45. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al.; LUME-Lung 1 Study Group (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143-155.
46. Reinmuth N, Heigener D, and Reck M (2015) Novel angiogenesis inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 27:79-86.
47. Reva B, Antipin Y, and Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118.
48. Rocco G, Morabito A, Leone A, Muto P, Fiore F, and Budillon A (2016) Management of non-small cell lung cancer in the era of personalized medicine. Int J Biochem Cell Biol 78:173-179.
49. Stankov K, Popovic S, and Mikov M (2014) C-KIT signaling in cancer treatment. Curr Pharm Des 20:2849-2880.
50. Stukalin I, Alimohamed N, and Heng DY (2016) Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev 10:295.
51. Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, Goto K, Suzuki Y, Ishii G, et al. (2013) Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci 104:896-903.
52. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, and Pachter L (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:511-515.
53. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93.
54. Winterhoff B and Konecny GE (2017) Targeting fibroblast growth factor pathways in endometrial cancer. Curr Probl Cancer 41:37-47.
55. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189.